First Published Paper for the SENS Research Foundation Mitochondria Team

For most of the past decade the SENS Research Foundation has helped to fund work by various groups on allotopic expression of mitochondrial genes, a way to both cure mitochondrial disease and, more importantly, prevent mitochondrial DNA damage from contributing to the aging process. Allotopic expression works by creating backup copies of important mitochondrial genes in the cell nucleus, altered such that the resulting proteins can make their way back to the mitochondria where they are needed. Some of that work gave rise to Gensight in France, where researchers are commercializing the ability to move one of these genes into the nucleus. Last year a crowdfunding initiative provided the funds for the SENS Research Foundation in-house scientific team to finalize demonstration of allotopic expression of two more genes. The open access paper resulting from that work was recently accepted for publication, and here it is:

Mitochondria carry out oxidative phosphorylation principally by using pyruvate, fatty acids and amino acids to generate adenosine triphosphate (ATP). In animals, mitochondria are the only cellular organelles that possess their own DNA, mitochondrial DNA (mtDNA), which in humans contains 37 genes including genes encoding mitochondrial tRNAs, mitochondrial rRNAs and 13 oxidative phosphorylation (OxPhos) complex proteins. Both pediatric and adult-onset diseases have been identified that are caused by point mutations or partial deletions in mtDNA. Mitochondrial diseases tend to be fairly complex, with patients often presenting with multiple symptoms, and/or suffering from symptoms that differ between patients with the same mtDNA mutation. Traditional approaches include palliative treatments such as surgery or drugs, but are of limited use for mitochondrial diseases because they fail to address the underlying defect in the mtDNA.

Gene therapy may have the potential to treat mitochondrial disease, but many challenges exist. Direct transfection of replacement genes into mitochondria is extremely challenging. As an alternative, allotopic expression (the translocation of genes from their normal location in the mitochondria to the nucleus, followed by expression in the cytoplasm and re-insertion into the correct location in the mitochondria) was proposed as a potential method of gene therapy for congenital mutations over 25 years ago. This technique introduces additional challenges as, in addition to transfection into the cell, the allotopically expressed gene product must also translocate to the mitochondria and integrate into the appropriate protein complex. Nature already uses such targeting methods with the vast majority of proteins that comprise the mitochondrial proteome that are encoded by the nuclear genome.

In the time since allotopic expression of mitochondrially-encoded proteins was first proposed, several groups have attempted the method with mixed results. ATP6 protein was shown to integrate into Complex V (CV) and partially rescue growth of ATP6 mutant cells. ATP6 expression was also able to partially rescue mutant CHO cells while exogenous ND4 expression has been claimed to rescue rodent models of Leber's hereditary optic neuropathy. Mutant MT-ND1 cells were complemented by allotopic expression of ND1 with dramatic changes in the bioenergetics state and tumorgenic potential of the mutant cells. On the other hand, allotopically expressed ND6 protein localized to the mitochondria but failed to import properly or complement the loss of ND6 function. Allotopically expressed CYB was found to be similarly difficult to import into the mitochondria.

In order to unequivocally demonstrate functional import of a codon-corrected mtDNA gene, we sought to work in a system that was completely null for a mitochondrially encoded protein. We chose a transmitochondrial cybrid cell line which was derived from a patient whose mtDNA contained a nonsense mutation in ATP8. We have further characterized the cells and found them to contain reduced levels of ATP6 protein. Here, we demonstrate stable protein expression and mitochondrial import of ATP6 and ATP8 in the mutant cells. Tests for ATP hydrolysis / synthesis, oxygen consumption, glycolytic metabolism and viability all indicate a significant functional rescue of the mutant phenotype (including re-assembly of Complex V) following stable co-expression of ATP8 and ATP6.



Fantastic this is accelerated evolution in a very real sense! let us hope the remaining 11 genes are also transfered to join them soon. For all the critics eg, Blakemore who said in his 2008 this was highly unlikely to happen any time soon and slammed the SENS approach this paper is the cherry on the cake! Bravo to Oki and the team :)

Posted by: Steve Hill at September 6th, 2016 8:52 AM

I do hope our resident troll sees this because this is proof of concept for SENS and it isnt something in the distant future as our would be fortune teller would have us believe. I love it when experts and laymen predict something cannot be done, because it is usually the precursor to being proven wrong lol

Posted by: Steve Hill at September 6th, 2016 10:11 AM

So then it is bacterial enzymes that are being used to slice the mt gene from its existing position and move it into action??? I asked Elena earlier when she had posted this link on several of my FB groups. Now I received the link again by way of private message from a FB friend. So I just want to understand with my at times slow biological mind the means of the process.

Posted by: rodney berry at September 6th, 2016 4:17 PM

Seriously excellent news especially when you look at the progress in senescent cell clearance so SENS is really coming together. I think this all confirms Aubrey de Grey was right where so many were wrong although in fairness it all seemed pretty logical to me from the outset.

Posted by: John Andersen at September 7th, 2016 1:07 PM

Steve hill:
I hope you arent referring to me as the "resident troll"! But just in case you are, I would respond by saying that this achievement is only a tiny incremental step. It has only been performed in mice, and no reverse-aging affects have been seen. So this is a very long way from being clinically useful, if it ever will be. And this is only one aspect of SENS...

Posted by: MissKaioshin at September 8th, 2016 8:18 PM


Don't you have anything else to do besides critize the work that is being done by the SENS projects and other work on the anti-aging. You add zero value to this blog, only negative comments. Yes, you are the resident troll. So, not only are you negative, but naive too.

Posted by: Robert Church at September 9th, 2016 12:51 AM

@MissKaioshin Yes I am talking about you. You are a troll, you are often here so therefore you are our resident troll.

Not even going to respond to your "Expert" opinion of the results. You are not qualified in a relavant field so I can safely ignore your opinion just as everyone else here and on Reddit does. Your downvote score does not lie :)

In other news there is an AMA for MitoSENS Monday 12th 11am PST to discuss this! Perhaps our troll should come along and learn something :)

Posted by: Steve Hill at September 9th, 2016 5:53 AM

Even if it doesn't have an immediate clinical use for aging there are people suffering from inherited diseases which now have a prospective treatment they could look forward too.

Seeing how the first gene therapies for similar inherited disease cost around half a million dollars per child treated in Europe I think SENS could look at a lucrative deal in the future.

They did test the therapy on a human cell line with a mutation by the way.

Posted by: Anonymoose at September 9th, 2016 7:45 AM

@Anonymoose For anyone who has actually bothered reading the paper and more importantly those who understand it (clearly our friend has not) this information is plain to see. The mistaken belief this is only in mice shows they clearly didnt read it properly or at all. Now lets not feed the troll any more :)

Posted by: Steve Hill at September 9th, 2016 8:55 AM

Post a comment; thoughtful, considered opinions are valued. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.